Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- February 6, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- January 26, 2024 Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
- January 8, 2024 Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
- January 5, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- January 2, 2024 Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- December 28, 2023 Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
- December 14, 2023 Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
- December 11, 2023 EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
- December 6, 2023 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- November 21, 2023 Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
Displaying 11 - 20 of 279